RxDoctor Payments Data

Richard Valenzuela, MD

Family Medicine · Jacksonville, FLNPI 1174591424

Payments from drug & device makers

$11,058in general payments, 2019–2025

Across 672 payments — averaging $16.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Amgen$1K
  • Lilly USA, LLC$1K
  • AbbVie$894
  • AstraZeneca$774
  • Boehringer Ingelheim$741
  • plus $4K from 43 others

What the payments were for

  • Food & beverage$11,058100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,058 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$78,237
Medicare patients
271
Services billed
1,285

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide119$161,524
MounjaroTirzepatide65$88,866
JardianceEmpagliflozin56$84,651
EliquisApixaban64$68,946
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$36,321
JanuviaSitagliptin Phosphate16$24,150
NuedextaDextromethorphan Hbr/Quinidine13$23,674
FarxigaDapagliflozin Propanediol20$16,239
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr28$15,844
TrulicityDulaglutide12$14,351
Tresiba Flextouch U-200Insulin Degludec15$11,132
Repatha SureclickEvolocumab11$8,268
Rosuvastatin Calcium330$2,712
Atorvastatin Calcium360$2,696
Gabapentin121$2,257

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,903$161,524119 claims
Lilly USA, LLCMounjaro, Trulicity, Humulin 70-30$1,086$104,68788 claims
Boehringer IngelheimJardiance$741$84,65156 claims
PfizerEliquis$422$68,94664 claims
GSKTrelegy Ellipta, Anoro Ellipta$415$52,16567 claims
MerckJanuvia$104$24,15016 claims
Avanir Pharmaceuticals, Inc.Nuedexta$56$23,67413 claims
AstraZenecaFarxiga$774$16,23920 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →